Next Article in Journal
Systematic Preserflo MicroShunt Intraluminal Stenting for Hypotony Prevention in Highly Myopic Patients: A Comparative Study
Previous Article in Journal
Liver X Receptor Agonist Inhibits Oxidized Low-Density Lipoprotein Induced Choroidal Neovascularization via the NF-κB Signaling Pathway
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 12
Issue 4
10.3390/jcm12041676
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Predictive Role of hsCRP in Recurrent Stroke Differed According to Severity of Cerebrovascular Disease: Analysis from a Prospective Cohort Study

by
Jiejie Li
1,2,
Yuesong Pan
1,2,
Mengxing Wang
1,2,
Xia Meng
1,2,
Jinxi Lin
1,2,
Zixiao Li
1,2,
Hao Li
1,2,
Yilong Wang
1,2,
Xingquan Zhao
1,2,
Liping Liu
1,2 and
Yongjun Wang
3,4,*
1
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China
2
China National Clinical Research Center for Neurological Diseases, Beijing 100070, China
3
Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing 100070, China
4
Clinical Center for Precision Medicine in Stroke, Capital Medical University, Beijing 100070, China
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2023, 12(4), 1676; https://doi.org/10.3390/jcm12041676
Submission received: 27 December 2022 / Revised: 26 January 2023 / Accepted: 16 February 2023 / Published: 20 February 2023
(This article belongs to the Section Clinical Neurology)
Versions Notes

Abstract

:
Elevated levels of high-sensitivity C-reactive protein (hsCRP) were associated with an increased risk of recurrent stroke. However, it is still unknown whether the predictive value of hsCRP differed according to the severity of cerebrovascular disease. We used the cohort of the prospective multicenter cohort study of the Third China National Stroke Registry (CNSR-III), in which 10,765 consecutive patients with acute ischemic stroke or transient ischemic attack (TIA) had hsCRP levels measured. Patients were classified into minor stroke, or TIA, and non-minor stroke. The primary outcome was a new stroke within 1 year. Cox proportional hazards models were used to assess the association of hsCRP and its outcome. Elevated levels of hsCRP were associated with an increased risk of recurrent stroke in minor stroke or TIA patients, irrespective of using a National Institutes of Health Stroke Scale (NIHSS) score of ≤3 (the highest quartile vs. the lowest quartile: adjusted hazard ratio, 1.48; 95% CI, 1.12–1.97; p = 0.007) or ≤5 (the highest quartile vs. the lowest quartile: adjusted hazard ratio, 1.45; 95% CI, 1.15–1.84; p = 0.002) to define minor stroke. Such association was more apparent in the large-artery atherosclerosis subtype. However, for the patients with non-minor stroke, the association of hsCRP with recurrent stroke disappeared.

1. Introduction

Ischemic stroke and transient ischemic attack (TIA) are characterized by early recurrence, which may be fatal or disabling. The rate of recurrent stroke is reported to be around 10% within 3 months after the index event [1,2,3]. Early identification of patients at high-risk of recurrence is of clinical importance.
Inflammation contributes to the residual risk of recurrent stroke [4,5]. High-sensitive C-reactive protein (hsCRP), a well-known inflammatory marker, was shown to be potential in predicting the risk of recurrent stroke among patients with ischemic stroke or TIA in our and others’ previous studies [6,7,8,9,10,11,12,13,14,15,16,17]. High similarities between TIA and minor stroke in patients’ clinical characteristics and the more unstable status for recurrence suggested to dispense with distinction between them, and some large clinical trials have been initiated for early intensive secondary prevention in these high-risk patients [4,18,19,20,21]. Furthermore, we previously showed that hsCRP helped to stratify the risk of recurrent stroke in patients with TIA and minor stroke [22]. However, as an acute-phase protein, CRP was correlated with brain damage, which was directly reflected by severity of stroke or TIA clinically [23]. Although a few studies assessed the association between hsCRP and stroke recurrence, it remains unclear whether the predictive effect of hsCRP on recurrent stroke differed according to the severity of stroke.
Using data from the Third China National Stroke Registry (CNSR-III), we investigate whether the association between hsCRP and recurrent stroke is affected by the severity of cerebrovascular disease.

2. Methods

2.1. Study Design and Participants

The design of the CNSR-III has been described previously in detail [24]. Briefly, the CNSR-III was a nationwide prospective registry performed within seven days that included patients with acute ischemic stroke and TIA. Among 201 study sites from 22 provinces and 4 municipalities, 171 (85%) prespecified centers voluntarily participated in the pre-specified biomarker sub-study. The CNSR-III was approved by the ethics committee at Beijing Tiantan Hospital and participating centers. All participants or their legal proxies provided written informed consent.

2.2. Baseline Data Collection

At each study site, information on the participants’ age, sex, body mass index (BMI, the weight in kilograms divided by the square of the height in meters), cigarette-smoking history, medical history of hypertension, hypercholesterolemia, diabetes, ischemic stroke and coronary heart disease, and NIHSS score were collected at admission through a direct interview by trained research coordinators. We performed centralized etiology classification of ischemic stroke according to the TOAST (Trial of ORG 10,172 in Acute Stroke Treatment) criteria as described before [25,26].

2.3. Sample Collection and Measurement of hsCRP

Fasting blood specimens were collected within 24 h after enrollment. The median time of sampling was 55 h (interquartile range: 27–96 h) after index event onset. All specimens were extracted and transported through cold chain to the core laboratory in Beijing Tiantan Hospital. All specimens were stored at −80 ℃. Assays were performed centrally and blindly. Serum hsCRP was centrally measured on a Roche Cobas C701 analyzer with a lower limit of quantitation of 0.15 mg/L.

2.4. Follow-Up and Outcomes

Participants were followed up by face-to-face or telephone interviews at the 1-year mark by trained research personnel, collecting information on stroke recurrence and cardiovascular events during the follow-up period. Confirmation of recurrent stroke was sought from the treating hospital, and suspected recurrence without hospitalization was judged by the independent endpoint judgment committee. The primary outcome was a new stroke event (ischemic or hemorrhagic) within 1 year. The secondary outcome was death within 1 year.

2.5. Statistical Analysis

The distribution of hsCRP was skewed. We presented categorical variables as percentages and continuous variables as medians with interquartile ranges. Skewed continuous variables and ordinal variables were compared with the Kruskal–Wallis test. Chi square statistic or Fisher exact test was used for comparisons of categorical variables as appropriate.
While minor stroke was of clinical importance, it was defined through various definitions. A National Institutes of Health Stroke Scale (NIHSS) score of ≤3 [4,19,20] or ≤5 [27,28,29] was the most frequently used one. Minor stroke was therefore defined by two criteria separately in the current study: a NIHSS score of ≤3 or ≤5 at the time of admission [22,30,31]. The hsCRP level was assessed according to quartiles: quartile 1: <0.82 mg/L, quartile 2: 0.82 to 1.78 mg/L, quartile 3:1.78 to 4.72 mg/L, and quartile 4: >4.72 mg/L, or as a continuous variable after logarithm transformation. In addition, the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) study and the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial defined high-risk patients through the hsCRP cutoff level of ≥2 mg/L, which we therefore used as our cut-point as well [32,33]. The associations of hsCRP with recurrence and death were analyzed with the use of multivariable Cox proportional hazards models and logistic regression models. The potential confounders were age, sex, body mass index, smoking history, index event, medical histories of atrial fibrillation, coronary heart disease, ischemic stroke, diabetes, hypertension and hypercholesterolemia, baseline NIHSS score, baseline leukocyte count and low-density lipoprotein cholesterol level, usage of antiplatelet, antihypertensive, hypoglycemic and statin during a 1-year follow-up period, TOAST subtype, onset-to-sample collection time, intravenous recombinant tissue plasminogen activator treatment, and endovascular therapy. The unadjusted and adjusted hazard ratios (HRs) and their 95% confidence intervals (CIs) were calculated. A two-sided p value of <0.05 was considered to indicate statistical significance. SAS software, version 9.4 (SAS Institute, Inc., Cary, NC, USA) was used for all statistical analyses.

3. Results

3.1. Patient Characteristics

In the biomarker sub-study of CNSR-III, 10,765 (71.0%) patients with ischemic stroke or TIA had hsCRP measurement. Among them, 5055 and 7073 patients had minor stroke by using definitions of NIHSS score ≤3 and ≤5, and 735 patients had TIA. A total of 263 (2.4%) patients were lost to follow-up within one year. The baseline characteristics mostly differed between the patients with non-minor stroke and those with minor stroke (NIHSS ≤3 or ≤5) and TIA (Supplementary Table S1). The patients with minor stroke (NIHSS ≤ 3) or TIA and higher levels of hsCRP were significantly older and female, had higher BMI and baseline NIHSS score and LDL-C level, had histories of ischemic stroke, diabetes, hypertension, hypercholesterolemia, coronary heart disease and atrial fibrillation and minor stroke as a qualifying event, and received endovascular therapy and antihypertensive and hypoglycemic treatment during the follow-up (Table 1). Similar characteristics were observed when using the definition of NIHSS ≤ 5 to define minor stroke (Table 1).

3.2. Associations between hsCRP and Recurrent Stroke

A total of 485 (8.4%) and 715 (9.2%) patients, respectively, using NIHSS ≤ 3 and NIHSS ≤ 5 definitions, had subsequent stroke within 1 year (p = 0.12).
The elevated level of hsCRP was correlated with the incremental risk of recurrent stroke in the whole cohort (Table 2). When classifying patients according to severity, after adjustment for potential confounding factors, including onset-to-sample collection time and rt-PA and endovascular treatment, which was shown to affect hsCRP levels [34] and the predictive role of hsCRP in recurrent stroke or death [35,36], a consistent association between hsCRP and recurrence was observed in the patients with minor stroke or TIA, irrespective of using NIHSS score of ≤3 (the highest quartiles vs. the lowest quartiles: adjusted HR, 1.48; 95% CI, 1.11–1.96; p = 0.007; ≥2 mg/L vs. <2 mg/L: adjusted HR, 1.29; 95% CI, 1.06–1.57; p = 0.01; continuous model: adjusted HR, 1.13; 95% CI, 1.05–1.23; p = 0.001) or ≤5 (the highest quartiles vs. the lowest quartiles: adjusted HR, 1.45; 95% CI, 1.14–1.83; p = 0.002; ≥2 mg/L vs. <2 mg/L: adjusted HR, 1.24; 95% CI, 1.05–1.46; p = 0.01; continuous model: adjusted HR, 1.13; 95% CI, 1.06–1.20; p = 0.0002) to define minor stroke. However, for the patients with non-minor stroke, the association of hsCRP with recurrent stroke disappeared after adjustment. (Table 2)
The association of hsCRP with recurrent stroke was therefore further analyzed according to TOAST subtypes in the patients with minor stroke or TIA. An increased level of hsCRP was associated with recurrence in large-artery atherosclerosis subtype but not others, more apparently when using NIHSS score ≤5 definition (Table 3 and Supplementary Table S2).

3.3. Associations between hsCRP and Death

In total, 361 (3.4%) patients died within 1 year. Patients with higher hsCRP levels had an increased risk of death (Supplementary Table S3). Such association persisted in the patients with minor stroke or TIA, and non-minor stroke (Supplementary Table S3).

4. Discussion

In the current study, we found that the predictive role of hsCRP in recurrent stroke differed according to the severity of cerebrovascular disease. An elevated hsCRP level was correlated with an increased risk of recurrent stroke in the patients with TIA or minor stroke, irrespective of using NIHSS score of ≤3 or ≤5 to define minor stroke. However, such a relationship was attenuated in the patients with non-minor stroke. The association between hsCRP level and dependence or death appeared to maintain, regardless of severity.
Contrary to a line of research illustrating the association between hsCRP and recurrence after stroke, few studies assessed its role in recurrent stroke in specific high-risk patients with minor stroke or TIA, and yielded conflicting results [22,37]. Difference in the sample size and the definition of minor stroke might explain the controversy. For practical purposes, the NIHSS score was utilized as the evaluation scale to determine the severity of stroke. Various definitions of minor stroke has been proposed, among which NIHSS score ≤3 had the best outcomes [38]. Consistent with our prior study using NIHSS scores ≤3 [15], we found a significant relationship between hsCRP and recurrent stroke in the patients with TIA or minor stroke in the current study. Besides that, NIHSS score ≤5 was another commonly used definition of minor stroke [27,28,29]. In addition to proving our previous research, which showed that the two definitions had comparable clinical characteristics [39], our present study further added evidence that hsCRP had similar predictive values in stroke recurrence using these two definitions. However, such a relationship was apparently attenuated in the patients with non-minor stroke.
Atherosclerosis is a complex inflammatory disease [40]. CRP is an acute-phase protein produced in the liver, and also reflects chronic inflammation, including atherosclerosis burden [41]. Besides that, CRP has been shown to participate in inflammation response after acute stroke via modulating plaque instability, platelet activity, and thrombosis [42], which eventually leads to recurrent vascular events [43]. The relationship between CRP and recurrent stroke has been indicated in previous clinical research [6,7,8,9,10,11,12,13,14,15,16,17]. Some explanations might be given for the impact of hsCRP on recurrence being modulated by stroke severity. Besides vascular inflammation, brain damage and stress were also mainly composed of acute phase inflammation response. It was indicated that the magnitude of acute inflammation response to brain ischemia was related to the volume of infarcted brain. A correlation between CRP and infarct size and severity of stroke per se has been described before [22,23]. Therefore, for the patients with non-minor stroke, it is conceivable that an elevated hsCRP level after stroke could mainly be owing to inflammation related to the pathophysiology of ischemic stroke with a relatively large ischemic area, towering over that triggered by vascular inflammation, the main factor leading to recurrence [44]. Whereas, for minor stroke or TIA with mild ischemia, acute individual inflammation response could be weak, and the increased hsCRP levels may primarily reflect activation of vascular inflammation, which were closely associated with recurrence. This hypothesis was supported by our findings that the association between hsCRP levels and recurrent stroke in the patients with minor stroke or TIA was more apparent in larger-artery atherosclerosis subtype, in line with a prior study which indicated that hsCRP predicted subsequent ischemic events in the patients with intracranial large-artery occlusive disease [7]. Meanwhile, the association between hsCRP and brain ischemic damage maintained regardless of stroke severity, which directly influenced survival. This might be one reason for the persisting significant relationship between hsCRP and death in our study. Though these hypotheses needed to be verified in further studies, our results at least suggested the different mechanisms in hsCRP leading to recurrence and functional outcome.
Thanks to a series of measures, the recurrence rate after minor stroke or TIA declined during the last decade. In the CHANCE trial, the rate dropped from 11.7% to 8.2% by the usage of dual anti-platelet therapy, which was similar to the rate in our study. Combined with the observation that around 98% and 99% patients received anti-platelet agent and statin during follow-up, our data suggested a good adherence to the guideline of secondary prevention in China [45]. However, the residual recurrent risk remained and warranted additional treatment. The effect of anti-inflammation treatment on recurrent cardiovascular disease has been proven recently in large clinical trials [46,47] and is being tested in the patients with non-severe stroke [21]. Our findings help in accurately implying hsCRP to stratify the risk of recurrent stroke, by providing data for potential secondary prevention targets for minor stroke or TIA, as well as in providing evidence in choosing patients for anti-inflammatory therapy.
Though our study derived from a prospective, multicenter, and large sample-sized cohort and centrally-measured blood samples, it also had several limitations. First, the measurement of hsCRP level was only performed at baseline, disenabling us to investigate the effect of hsCRP change on prognosis. Second, though the adherence to secondary prevention was good, information about how the traditional risk factors of blood pressure and blood glucose and lipids levels were controlled during follow-up was unavailable. Third, NIHSS scores often do not reflect the true size of brain lesions. A measurement of brain lesion volume would be more informative. Fourthly, only the Chinese population was enrolled in our study, thus, our findings may not be generalizable to other races and ethnicities.

5. Conclusions

Elevated hsCRP levels were related to an increased risk of recurrent stroke in the patients with TIA or minor stroke. However, such a relationship was not found in the patients with non-minor stroke.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm12041676/s1, Table S1: Distribution of Baseline Characteristics According to Severity of Cerebrovascular Disease; Table S2: Association of hsCRP and Recurrent Stroke in Different TOAST Subtype beyond Large-artery Atherosclerosis Among the Patients with Varying Definition of Minor Stroke or TIA; Table S3: Association of hsCRP and Death according to NIHSS Score.

Author Contributions

Conceptualization, J.L. (Jiejie Li), J.L. (Jinxi Lin), H.L. and Y.W. (Yongjun Wang); methodology, J.L. (Jiejie Li), Y.P., M.W., J.L. (Jinxi Lin), H.L., X.M., Z.L., Y.W. (Yilong Wang), X.Z., L.L. and Y.W. (Yongjun Wang); validation, Y.P. and M.W.; formal analysis, Y.P. and M.W.; investigation, J.L. (Jiejie Li), Y.P., M.W., J.L. (Jinxi Lin), H.L., X.M., Z.L., Y.W. (Yilong Wang), X.Z., L.L. and Y.W. (Yongjun Wang); resources, X.M., Z.L., Y.W. (Yilong Wang), X.Z., L.L. and Y.W. (Yongjun Wang); data curation, Y.P., M.W. and H.L.; writing—original draft preparation, J.L. (Jiejie Li); writing—review and editing, Y.P., M.W., J.L. (Jinxi Lin), H.L., X.M., Z.L., Y.W. (Yilong Wang), X.Z., L.L. and Y.W. (Yongjun Wang); supervision, H.L., X.M., Z.L., Y.W. (Yilong Wang), X.Z., L.L. and Y.W. (Yongjun Wang); project administration, H.L., X.M., Z.L., Y.W. (Yilong Wang), X.Z., L.L. and Y.W. (Yongjun Wang); funding acquisition, Y.W. (Yongjun Wang). All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by grants from the National Natural Science Foundation of China (81870905, U20A20358), the Capital’s Funds for Health Improvement and Research (2020-1-2041) and the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (2019-I2M-5-029).

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of Beijing Tiantan Hospital (protocol code: KY2015-001-01; date of approval: 12 February 2015).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

All data are stored in China National Clinical Research Center for Neurological Diseases and are available to researchers upon reasonable request by directly contacting the corresponding author.

Acknowledgments

We thank all participating hospitals, physicians and nurses, and the CNSR-III Steering Committee members.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Lovett, J.K.; Coull, A.J.; Rothwell, P.M. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004, 62, 569–573. [Google Scholar] [CrossRef] [PubMed]
  2. Kleindorfer, D.; Panagos, P.; Pancioli, A.; Khoury, J.; Kissela, B.; Woo, D.; Schneider, A.; Alwell, K.; Jauch, E.; Miller, R.; et al. Incidence and Short-Term Prognosis of Transient Ischemic Attack in a Population-Based Study. Stroke 2005, 36, 720–723. [Google Scholar] [CrossRef] [PubMed]
  3. Xu, J.; Zhang, X.; Jin, A.; Pan, Y.; Li, Z.; Meng, X.; Wang, Y. Trends and Risk Factors Associated With Stroke Recurrence in China, 2007-2018. JAMA Netw. Open 2022, 5, e2216341. [Google Scholar] [CrossRef]
  4. Li, J.; Pan, Y.; Xu, J.; Li, S.; Wang, M.; Quan, K.; Meng, X.; Li, H.; Lin, J.; Wang, Y.; et al. Residual Inflammatory Risk Predicts Poor Prognosis in Acute Ischemic Stroke or Transient Ischemic Attack Patients. Stroke 2021, 52, 2827–2836. [Google Scholar] [CrossRef] [PubMed]
  5. Wang, Y. Residual recurrence risk of ischaemic cerebrovascular events: Concept, classification and implications. Stroke Vasc. Neurol. 2021, 6, 155–157. [Google Scholar] [CrossRef]
  6. Li, J.; Lin, J.; Pan, Y.; Wang, M.; Meng, X.; Li, H.; Wang, Y.; Zhao, X.; Qin, H.; Liu, L.; et al. Interleukin-6 and YKL-40 predicted recurrent stroke after ischemic stroke or TIA: Analysis of 6 inflammation biomarkers in a prospective cohort study. J. Neuroinflamm. 2022, 19, 131. [Google Scholar] [CrossRef] [PubMed]
  7. Arenillas, J.F.; Alvarez-Sabin, J.; Molina, C.A.; Chacón, P.; Montaner, J.; Rovira, A.; Ibarra, B.; Quintana, M. C-Reactive Protein Predicts Further Ischemic Events in First-Ever Transient Ischemic Attack or Stroke Patients With Intracranial Large-Artery Occlusive Disease. Stroke 2003, 34, 2463–2468. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  8. Corso, G.; Bottacchi, E.; Brusa, A.; Benedetto, M.D.; Giardini, G.; Lia, C.; Reggiani, M.; Veronese Morosini, M. Is there a prognostic role for c-reactive protein in ischemic stroke? Acta Neurol. Scand. 2010, 122, 209–216. [Google Scholar] [CrossRef] [PubMed]
  9. Corso, G.; Bottacchi, E.; Brusa, A.; Lia, C.; Cordera, S.; Giardini, G.; Campagnoni, M.P.; Morosini, M.V. Blood C-Reactive Protein Concentration with ABCD2 Is a Better Prognostic Tool than ABCD2 Alone. Cerebrovasc. Dis. 2011, 32, 97–105. [Google Scholar] [CrossRef]
  10. Elkind, M.S.V.; Luna, J.M.; McClure, L.A.; Zhang, Y.; Coffey, C.S.; Roldan, A.; Del Brutto, O.H.; Pretell, E.J.; Pettigrew, L.C.; Meyer, B.C.; et al. C-reactive protein as a prognostic marker after lacunar stroke: Levels of inflammatory markers in the treatment of stroke study. Stroke 2014, 45, 707–716. [Google Scholar] [CrossRef] [Green Version]
  11. Purroy, F.; Montaner, J.; Molina, C.A.; Delgado, P.; Arenillas, J.F.; Chacon, P.; Quintana, M.; Alvarez-Sabin, J. C-reactive protein predicts further ischemic events in transient ischemic attack patients. Acta Neurol. Scand. 2007, 115, 60–66. [Google Scholar] [CrossRef]
  12. Kuwashiro, T.; Sugimori, H.; Ago, T.; Kuroda, J.; Kamouchi, M.; Kitazono, T. For the FSR Investigators (see appendix) Predictive role of C reactive protein in stroke recurrence after cardioembolic stroke: The Fukuoka Stroke Registry. BMJ Open 2013, 3, e003678. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Kitagawa, K.; Hosomi, N.; Nagai, Y.; Kagimura, T.; Ohtsuki, T.; Origasa, H.; Minematsu, K.; Uchiyama, S.; Nakamura, M.; Matsumoto, M.; et al. Reduction in High-Sensitivity C-Reactive Protein Levels in Patients with Ischemic Stroke by Statin Treatment: Hs-CRP Sub-Study in J-STARS. J. Atheroscler. Thromb. 2017, 24, 1039–1047. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Segal, H.C.; Burgess, A.I.; Poole, D.L.; Mehta, Z.; Silver, L.E.; Rothwell, P.M. Population-Based Study of Blood Biomarkers in Prediction of Subacute Recurrent Stroke. Stroke 2014, 45, 2912–2917. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Williams, S.R.; Hsu, F.C.; Keene, K.L.; Chen, W.M.; Nelson, S.; Southerland, A.M.; Madden, E.B.; Coull, B.; Gogarten, S.M.; Furie, K.L.; et al. Shared genetic susceptibility of vascular-related biomarkers with ischemic and recurrent stroke. Neurology 2016, 86, 351–359. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Zhang, Y.-B.; Yin, Z.; Han, X.; Wang, Q.; Zhang, Z.; Geng, J. Association of circulating high-sensitivity C-reactive protein with late recurrence after ischemic stroke. Neuroreport 2017, 28, 598–603. [Google Scholar] [CrossRef]
  17. McCabe, J.; O’Reilly, E.; Coveney, S.; Collins, R.; Healy, L.; McManus, J.; Mulcahy, R.; Moynihan, B.; Cassidy, T.; Hsu, F.; et al. Interleukin-6, C-reactive protein, fibrinogen and risk of recurrence after ischaemic stroke: Systematic review and meta-analysis. Eur. Stroke J. 2021, 6, 62–71. [Google Scholar] [CrossRef]
  18. Dennis, M.S.; Bamford, J.M.; Sandercock, P.; Warlow, C.P. A comparison of risk factors and prognosis for transient ischemic attacks and minor ischemic strokes. The Oxfordshire Community Stroke Project. Stroke 1989, 20, 1494–1499. [Google Scholar] [CrossRef] [Green Version]
  19. Wang, Y.; Zhao, X. Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack. J. Vasc. Surg. 2013, 58, 1140. [Google Scholar] [CrossRef] [Green Version]
  20. Johnston, S.C.; Easton, J.D.; Farrant, M.; Barsan, W.; Conwit, R.A.; Elm, J.J.; Kim, A.S.; Lindblad, A.S.; Palesch, Y.Y. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N. Engl. J. Med. 2018, 379, 215–225. [Google Scholar] [CrossRef]
  21. Kelly, P.; Weimar, C.; Lemmens, R.; Murphy, S.; Purroy, F.; Arsovska, A.; Bornstein, N.M.; Czlonkowska, A.; Fischer, U.; Fonseca, A.C.; et al. Colchicine for prevention of vascular inflammation in non-cardioembolic stroke (convince)—Study protocol for a randomised controlled trial. Eur. Stroke J. 2021, 6, 222–228. [Google Scholar] [CrossRef] [PubMed]
  22. Purroy, F.; Suárez-Luis, I.; Cambray, S.; Farré, J.; Benabdelhak, I.; Mauri-Capdevila, G.; Sanahuja, J.; Quílez, A.; Begué, R.; Gil, M.I.; et al. The determination of copeptin levels helps management decisions among transient ischaemic attack patients. Acta Neurol. Scand. 2015, 134, 140–147. [Google Scholar] [CrossRef]
  23. Beamer, N.B.; Coull, B.M.; Clark, W.M.; Hazel, J.S.; Silberger, J.R. Interleukin-6 and interleukin-1 receptor antagonist in acute stroke. Ann. Neurol.: Off. J. American Neurol. Assoc. Child Neurol. Soc. 1995, 37, 800–805. [Google Scholar]
  24. Wang, Y.; Jing, J.; Meng, X.; Pan, Y.; Wang, Y.; Zhao, X.; Lin, J.; Li, W.; Jiang, Y.; Li, Z.; et al. The Third China National Stroke Registry (CNSR-III) for patients with acute ischaemic stroke or transient ischaemic attack: Design, rationale and baseline patient characteristics. Stroke Vasc. Neurol. 2019, 4, 158–164. [Google Scholar] [CrossRef] [PubMed]
  25. Adams, H.P., Jr.; Bendixen, B.H.; Kappelle, L.J.; Biller, J.; Love, B.B.; Gordon, D.L.; Marsh, E.E., 3rd. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993, 24, 35–41. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Suo, Y.; Jing, J.; Meng, X.; Li, Z.; Pan, Y.; Jiang, Y.; Yang, X.; Liu, H.; Yan, H.; Liu, L.; et al. Inconsistent centralised versus non-centralised ischaemic stroke aetiology. Stroke Vasc. Neurol. 2020, 5, 337–347. [Google Scholar] [CrossRef]
  27. Majidi, S.; Luby, M.; Lynch, J.K.; Hsia, A.W.; Benson, R.T.; Kalaria, C.P.; Nadareishvili, Z.; Latour, L.L.; Leigh, R. MRI-based thrombolytic therapy in patients with acute ischemic stroke presenting with a low NIHSS. Neurology 2019, 93, e1507–e1513. [Google Scholar] [CrossRef]
  28. Asdaghi, N.; Wang, K.; Ciliberti-Vargas, M.A.; Gutierrez, C.M.; Koch, S.; Gardener, H.; Dong, C.; Rose, D.Z.; Garcia, E.J.; Burgin, W.S.; et al. Predictors of thrombolysis administration in mild stroke: Florida-puerto rico collaboration to reduce stroke disparities. Stroke 2018, 49, 638–645. [Google Scholar] [CrossRef]
  29. Park, H.K.; Kim, B.J.; Han, M.K.; Park, J.M.; Kang, K.; Lee, S.J.; Kim, J.G.; Cha, J.K.; Kim, D.H.; Nah, H.W.; et al. One-year outcomes after minor stroke or high-risk transient ischemic attack: Korean multicenter stroke registry analysis. Stroke 2017, 48, 2991–2998. [Google Scholar] [CrossRef]
  30. Amarenco, P.; Lavallée, P.C.; Tavares, L.M.; Labreuche, J.; Albers, G.W.; Abboud, H.; Anticoli, S.; Audebert, H.; Bornstein, N.M.; Caplan, L.R.; et al. Five-Year Risk of Stroke after TIA or Minor Ischemic Stroke. N. Engl. J. Med. 2018, 378, 2182–2190. [Google Scholar] [CrossRef] [Green Version]
  31. Wang, Y.; Pan, Y.; Zhao, X.; Li, H.; Wang, D.; Johnston, S.C.; Liu, L.; Meng, X.; Wang, A.; Wang, C.; et al. Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial. Circulation 2015, 132, 40–46. [Google Scholar] [CrossRef] [PubMed]
  32. Ridker, P.M.; Danielson, E.; Fonseca, F.A.; Genest, J.; Gotto, A.M., Jr.; Kastelein, J.J.; Koenig, W.; Libby, P.; Lorenzatti, A.J.; MacFadyen, J.G.; et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N. Engl. J. Med. 2008, 359, 2195–2207. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Ridker, P.M.; Everett, B.M.; Thuren, T.; MacFadyen, J.G.; Chang, W.H.; Ballantyne, C.; Fonseca, F.; Nicolau, J.; Koenig, W.; Anker, S.D.; et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N. Engl. J. Med. 2017, 377, 1119–1131. [Google Scholar] [CrossRef]
  34. Winbeck, K.; Poppert, H.; Etgen, T.; Conrad, B.; Sander, D. Prognostic Relevance of Early Serial C-Reactive Protein Measurements After First Ischemic Stroke. Stroke 2002, 33, 2459–2464. [Google Scholar] [CrossRef]
  35. Wang, Y.; Li, J.; Pan, Y.; Wang, M.; Meng, X.; Wang, Y. Association Between High-Sensitivity C-Reactive Protein and Prognosis in Different Periods After Ischemic Stroke or Transient Ischemic Attack. J. Am. Heart Assoc. 2022, 11, e025464. [Google Scholar] [CrossRef]
  36. Kazmierski, R. Predictors of early mortality in patients with ischemic stroke. Expert Rev. Neurother. 2006, 6, 1349–1362. [Google Scholar] [CrossRef]
  37. Selvarajah, J.R.; Smith, C.J.; Hulme, S.; Georgiou, R.; Sherrington, C.; Staniland, J.; Illingworth, K.J.; Jury, F.; Payton, A.; Ollier, W.E.; et al. Does inflammation predispose to recurrent vascular events after recent transient ischaemic attack and minor stroke? The north west of england transient ischaemic attack and minor stroke (northstar) study. Int. J. Stroke 2011, 6, 187–194. [Google Scholar] [CrossRef] [PubMed]
  38. Fischer, U.; Baumgartner, A.; Arnold, M.; Nedeltchev, K.; Gralla, J.; De Marchis, G.M.; Kappeler, L.; Mono, M.-L.; Brekenfeld, C.; Schroth, G.; et al. What is a minor stroke? Stroke 2010, 41, 661–666. [Google Scholar] [CrossRef] [Green Version]
  39. Xiong, Y.; Gu, H.; Zhao, X.Q.; Yang, X.; Wang, C.; Wang, Y.L.; Liu, L.P.; Zhou, Q.; Fisher, M.; Li, Z.; et al. Clinical characteristics and in-hospital outcomes of varying definitions of minor stroke: From a large-scale nation-wide longitudinal registry. Stroke 2021, 52, 1253–1258. [Google Scholar] [CrossRef]
  40. Libby, P. Inflammation during the life cycle of the atherosclerotic plaque. Cardiovasc. Res. 2021, 117, 2525–2536. [Google Scholar] [CrossRef]
  41. Wang, J.; Liu, Y.; Zhang, L.; Li, N.; Wang, C.; Gao, X.; Zhou, Y.; Wang, A.; Wu, S.; Zhao, X. Associations of high sensitivity C-reactive protein levels with the prevalence of asymptomatic intracranial arterial stenosis. Eur. J. Neurol. 2014, 21, 512–518. [Google Scholar] [CrossRef]
  42. Gussekloo, J.; Schaap, M.C.L.; Fröich, M.; Blauw, G.J.; Westendorp, R.G.J. C-Reactive Protein Is a Strong but Nonspecific Risk Factor of Fatal Stroke in Elderly Persons. Arter. Thromb. Vasc. Biol. 2000, 20, 1047–1051. [Google Scholar] [CrossRef] [Green Version]
  43. Roth, S.; Singh, V.; Tiedt, S.; Schindler, L.; Huber, G.; Geerlof, A.; Antoine, D.J.; Anfray, A.; Orset, C.; Gauberti, M.; et al. Brain-released alarmins and stress response synergize in accelerating atherosclerosis progression after stroke. Sci. Transl. Med. 2018, 10, eaao1313. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Dirnagl, U.; Iadecola, C.; Moskowitz, M.A. Pathobiology of ischaemic stroke: An integrated view. Trends Neurosci. 1999, 22, 391–397. [Google Scholar] [CrossRef] [PubMed]
  45. Powers, W.J.; Rabinstein, A.A.; Ackerson, T.; Adeoye, O.M.; Bambakidis, N.C.; Becker, K.; Biller, J.; Brown, M.; Demaerschalk, B.M.; Hoh, B.; et al. 2018 guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2018, 49, e46–e110. [Google Scholar] [CrossRef] [PubMed]
  46. Nidorf, S.M.; Fiolet, A.T.L.; Mosterd, A.; Eikelboom, J.W.; Schut, A.; Opstal, T.S.J.; The, S.H.K.; Xu, X.-F.; Ireland, M.A.; Lenderink, T.; et al. Colchicine in Patients with Chronic Coronary Disease. N. Engl. J. Med. 2020, 383, 1838–1847. [Google Scholar] [CrossRef] [PubMed]
  47. Tardif, J.-C.; Kouz, S.; Waters, D.D.; Bertrand, O.F.; Diaz, R.; Maggioni, A.P.; Pinto, F.J.; Ibrahim, R.; Gamra, H.; Kiwan, G.S.; et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N. Engl. J. Med. 2019, 381, 2497–2505. [Google Scholar] [CrossRef]
Table
Table 1. Characteristics according to hsCRP levels among the patients with varying definition of minor stroke or TIA.
Table 1. Characteristics according to hsCRP levels among the patients with varying definition of minor stroke or TIA.
NIHSS ≤ 3 or TIA (n = 5790)NIHSS ≤ 5 or TIA (n = 7808)
hsCRP Q1hsCRP Q2hsCRP Q3hsCRP Q4p ValuehsCRP Q1hsCRP Q2hsCRP Q3hsCRP Q4p Value
Age (year), median (IQR)61 (53–68)61 (54–68)62 (53–70)64 (57–73)<0.000161 (53–68)61 (54–68)62 (54–70)65 (57–73)<0.0001
Male, No. (%)1198 (72.9)1133 (69.8)936 (65.7)764 (69.5)0.00041574 (72.8)1493 (69.8)1288 (66.0)1062 (68.3)<0.0001
BMI, median (IQR)24.2 (22.3–26.0)24.7 (22.9–26.8)25.0 (22.9–27.3)24.7 (22.9–27.0)<0.000124.2 (22.3–26.0)24.7 (22.9–26.7)24.9 (22.9–27.2)24.7 (22.9–26.8)<0.0001
Smoking, No. (%)746 (45.4)750 (46.2)624 (43.8)480 (43.7)0.451001 (46.3)971 (45.4)869 (44.5)673 (43.3)0.28
Medical history, No. (%)
Ischemic stroke296 (18.0)302 (18.6)256 (18.0)250 (22.8)0.007414 (19.2)410 (19.2)380 (19.5)359 (23.1)0.01
Diabetes363 (22.1)332 (20.5)370 (26.0)269 (24.5)0.002482 (22.3)459 (21.5)518 (26.5)399 (25.6)0.0002
Hypertension967 (58.8)999 (61.6)917 (64.4)724 (65.9)0.00061292 (59.8)1334 (62.4)1258 (64.4)1015 (65.2)0.002
Hypercholesterolemia129 (7.9)136 (8.4)154 (10.8)102 (9.3)0.03174 (8.1)175 (8.2)209 (10.7)132 (8.5)0.01
Coronary heart disease123 (7.5)128 (7.9)170 (11.9)144 (13.1)<0.0001176 (8.1)185 (8.7)234 (12.0)198 (12.7)<0.0001
Atrial fibrillation57 (3.5)84 (5.2)76 (5.3)100 (9.1)<0.000173 (3.4)113 (5.3)103 (5.3)144 (9.3)<0.0001
Index event 0.005 0.0004
Ischemic stroke1401 (85.2)1410 (86.9)1268 (89.0)976 (88.8) 1918 (88.8)1925 (90.0)1797 (92.0)1433 (92.1)
TIA243 (14.8)213 (13.1)156 (11.0)123 (11.2) 243 (11.2)213 (10.0)156 (8.0)123 (7.9)
Baseline NIHSS, median (IQR)1 (0–2)1 (0–2)2 (0–2)2 (1–2)0.0472 (1–3)2 (1–3)2 (1–4)2 (1–4)<0.0001
Leukocyte count (*109/L), Median (IQR)6.3 (5.3–7.5)6.7 (5.6–8.0)7.0 (5.9–8.7)7.4 (6.0–9.1)<0.00016.3 (5.3–7.5)6.7 (5.6–8.0)7.0 (5.8–8.6)7.5 (6.1–9.1)<0.0001
Intravenous rt-PA therapy, No. (%)82 (5.0)89 (5.5)85 (6.0)67 (6.1)0.55127 (5.9)132 (6.2)140 (7.2)122 (7.8)0.06
Endovascular therapy, No. (%)2 (0.1)4 (0.3)4 (0.3)10 (0.9)0.0043 (0.1)4 (0.2)6 (0.3)14 (0.9)0.0004
Medication within 1-year follow-up period, No. (%)
Antiplatelet agents1627 (99.0)1606 (99.0)1399 (98.2)1087 (98.9)0.222142 (99.1)2119 (99.1)1925 (98.6)1534 (98.6)0.17
Antihypertensive agents1016 (61.8)1051 (64.8)977 (68.6)739 (67.2)0.00051342 (62.1)1393 (65.2)1337 (68.5)1057 (67.9)<0.0001
Hypoglycemic agents415 (25.2)431 (26.6)458 (32.2)329 (29.9)<0.0001554 (25.6)593 (27.7)636 (32.6)499 (32.1)<0.0001
Statin1617 (98.4)1606 (99.0)1394 (97.9)1074 (97.7)0.0532126 (98.4)2117 (99.0)1917 (98.2)1528 (98.2)0.10
Abbreviation: IQR = interquartile range; NIHSS = National Institutes of Health Stroke Scale; mRS = modified Rankin Scale; hsCRP = high-sensitive C-reactive Protein; rt-PA = recombinant tissue plasminogen activator. The hsCRP values were categorized into four even levels by quartiles: quartile 1 (Q1): <0.82 mg/L; quartile 2 (Q2): 0.82 to 1.78 mg/L; quartile 3 (Q3):1.78 to 4.72 mg/L; quartile 4 (Q4): >4.72 mg/L.
Table
Table 2. Association of hsCRP and recurrent stroke according to severity of cerebrovascular disease.
Table 2. Association of hsCRP and recurrent stroke according to severity of cerebrovascular disease.
GrouphsCRP Levels *Events
N (%)		Model 1 †Model 2 ‡Model 3 §
HR (95% CI)p ValueHR (95% CI)p ValueHR (95% CI)p Value
All patients
n = 10,765		Q1220 (8.3)Reference/Reference/Reference/
Q2230 (8.5)1.03 (0.86–1.24)0.730.98 (0.81–1.18)0.810.98 (0.80–1.20)0.85
Q3269 (10.0)1.24 (1.04–1.48)0.021.09 (0.91–1.31)0.351.11 (0.91–1.36)0.29
Q4343 (12.7)1.62 (1.37–1.92)<0.00011.29 (1.07–1.54)0.0071.33 (1.09–1.62)0.005
<2 mg/L480 (8.4)Reference/Reference/Reference/
≥2 mg/L582 (11.6)1.42 (1.26–1.61)<0.00011.22 (1.07–1.39)0.0021.25 (1.09–1.44)0.002
Continuous model1.15 (1.10–1.20)<0.00011.08 (1.03–1.13)0.0011.10 (1.05–1.16)<0.0001
NIHSS ≤ 3 or TIA
n = 5790		Q1122 (7.4)Reference/Reference/Reference/
Q2119 (7.3)0.99 (0.77–1.28)0.960.98 (0.75–1.27)0.851.01 (0.76–1.34)0.93
Q3127 (8.9)1.23 (0.96–1.58)0.101.13 (0.87–1.47)0.351.18 (0.89–1.56)0.25
Q4117 (10.7)1.49 (1.15–1.92)0.0021.33 (1.02–1.74)0.041.48 (1.11–1.96)0.007
<2 mg/L260 (7.5)Reference/Reference/Reference/
≥2 mg/L225 (9.7)1.31 (1.10–1.57)0.0031.21 (1.003–1.46)0.0461.29 (1.05–1.57)0.01
Continuous model1.12 (1.05–1.20)0.0011.08 (1.004–1.16)0.041.13 (1.05–1.23)0.001
NIHSS > 3
n = 4975		Q198 (9.6)Reference/Reference/Reference/
Q2111 (10.2)1.07 (0.81–1.40)0.640.98 (0.75–1.30)0.910.95 (0.71–1.29)0.75
Q3142 (11.2)1.19 (0.92–1.54)0.191.03 (0.79–1.34)0.851.03 (0.77–1.37)0.84
Q4226 (14.2)1.56 (1.23–1.98)0.00021.20 (0.93–1.56)0.171.18 (0.90–1.57)0.24
<2 mg/L220 (9.7)Reference/Reference/Reference/
≥2 mg/L357 (13.2)1.41 (1.19–1.67)<0.00011.19 (0.99–1.43)0.071.19 (0.98–1.45)0.08
Continuous model1.13 (1.07–1.19)<0.00011.06 (1.000–1.13)0.061.07 (1.00–1.14)0.047
NIHSS ≤ 5 or TIA
n = 7808		Q1168 (7.8)Reference/Reference/Reference/
Q2176 (8.2)1.07 (0.86–1.32)0.551.02 (0.82–1.27)0.851.06 (0.84–1.34)0.63
Q3186 (9.5)1.25 (1.02–1.54)0.031.12 (0.90–1.39)0.301.14 (0.90–1.44)0.29
Q4185 (11.9)1.59 (1.29–1.96)<0.00011.39 (1.11–1.73)0.0041.45 (1.14–1.83)0.002
<2 mg/L369 (8.1)Reference/Reference/Reference/
≥2 mg/L346 (10.7)1.35 (1.17–1.57)<0.00011.22 (1.05–1.43)0.011.24 (1.05–1.46)0.01
Continuous model1.14 (1.08–1.20)<0.00011.09 (1.03–1.16)0.0031.13 (1.06–1.20)0.0002
NIHSS > 5
n = 2957		Q152 (10.3)Reference/Reference/Reference/
Q254 (9.4)0.91 (0.62–1.33)0.620.82 (0.56–1.21)0.310.73 (0.48–1.12)0.15
Q383 (11.3)1.11 (0.78–1.56)0.570.92 (0.65–1.32)0.670.95 (0.65–1.39)0.78
Q4158 (13.9)1.42 (1.04–1.94)0.031.01 (0.72–1.41)0.981.01 (0.70–1.46)0.95
<2 mg/L111 (9.6)Reference/Reference/Reference/
≥2 mg/L236 (13.2)1.43 (1.14–1.79)0.0021.15 (0.91–1.47)0.251.22 (0.94–1.59)0.14
Continuous model1.12 (1.05–1.20)0.00081.04 (0.96–1.12)0.361.05 (0.96–1.14)0.30
Patients were classified into minor stroke (NIHSS score ≤3 or ≤5) or TIA, and non-minor stroke (NIHSS score >3 or >5). * The hsCRP values were categorized into four even levels by quartiles: quartile 1 (Q1): <0.82 mg/L; quartile 2 (Q2): 0.82 to 1.78 mg/L; quartile 3 (Q3):1.78 to 4.72 mg/L; quartile 4 (Q4): >4.72 mg/L or two levels according to cut-off level of 2 mg/L. In the continuous model, the hazard ratios correspond to per unit increment of logarithm of the hsCRP value (mg/L). † Model 1: Unadjusted. ‡ Model 2: Adjusted for age, sex, body mass index, smoking history, index event, medical histories of atrial fibrillation, coronary heart disease, ischemic stroke, diabetes, hypertension and hypercholesterolemia, baseline NIHSS score, leukocyte count and low-density lipoprotein cholesterol levels, usage of antiplatelet, antihypertensive, hypoglycemic, and statin during the 1-year follow-up period and TOAST subtype. § Model 3: Adjusted for all factors in model 2, onset-to-sample collection time, intravenous recombinant tissue plasminogen activator treatment, and endovascular therapy.
Table
Table 3. Association of hsCRP and recurrent stroke in large-artery atherosclerosis subtype among the patients with varying definition of minor stroke or TIA.
Table 3. Association of hsCRP and recurrent stroke in large-artery atherosclerosis subtype among the patients with varying definition of minor stroke or TIA.
GrouphsCRP Levels *Events, No, (%)Model 1 †Model 2 ‡
HR (95% CI)p ValueHR (95% CI)p Value
NIHSS ≤ 3 or TIA
n = 1265		Q132 (10.7)Reference/Reference/
Q230 (8.8)0.82 (0.50–1.35)0.440.90 (0.51–1.58)0.71
Q330 (9.3)0.89 (0.54–1.46)0.630.97 (0.55–1.71)0.92
Q450 (16.7)1.64 (1.05–2.56)0.031.60 (0.95–2.69)0.08
<2 mg/L69 (10.1)Reference/Reference/
≥2 mg/L73 (12.6)1.28 (0.92–1.78)0.141.24 (0.86–1.80)0.25
Continuous model1.17 (1.04–1.32)0.011.16 (1.00–1.33)0.049
NIHSS ≤ 5 or TIA
n = 1752		Q140 (9.9)Reference/Reference/
Q247 (10.0)1.02 (0.67–156)0.921.21 (0.75–1.96)0.44
Q345 (9.9)1.02 (0.66–1.56)0.941.15 (0.70–1.89)0.57
Q473 (17.2)1.84 (1.25–2.70)0.0021.84 (1.15–2.93)0.01
<2 mg/L96 (10.3)Reference/Reference/
≥2 mg/L109 (13.3)1.32 (1.01–1.74)0.051.23 (0.89–1.68)0.21
Continuous model1.20 (1.09–1.33)0.00031.20 (1.07–1.35)0.003
* The hsCRP values were categorized into four even levels by quartiles: quartile 1 (Q1): <0.82 mg/L; quartile 2 (Q2): 0.82 to 1.78 mg/L; quartile 3 (Q3):1.78 to 4.72 mg/L; quartile 4 (Q4): >4.72 mg/L or two levels according to cut-off level of 2 mg/L. In the continuous model, the hazard ratios correspond to per unit increment of logarithm of the hsCRP value (mg/L). † Model 1: Unadjusted. ‡ Model 2: Adjusted for age, sex, body mass index, smoking history, index event, medical histories of atrial fibrillation, coronary heart disease, ischemic stroke, diabetes, hypertension and hypercholesterolemia, baseline NIHSS score, leukocyte count and low-density lipoprotein cholesterol levels, usage of antiplatelet, antihypertensive, hypoglycemic and statin during the 1-year follow-up period, onset-to-sample collection time, intravenous recombinant tissue plasminogen activator treatment, and endovascular therapy.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Li, J.; Pan, Y.; Wang, M.; Meng, X.; Lin, J.; Li, Z.; Li, H.; Wang, Y.; Zhao, X.; Liu, L.; et al. Predictive Role of hsCRP in Recurrent Stroke Differed According to Severity of Cerebrovascular Disease: Analysis from a Prospective Cohort Study. J. Clin. Med. 2023, 12, 1676. https://doi.org/10.3390/jcm12041676

AMA Style

Li J, Pan Y, Wang M, Meng X, Lin J, Li Z, Li H, Wang Y, Zhao X, Liu L, et al. Predictive Role of hsCRP in Recurrent Stroke Differed According to Severity of Cerebrovascular Disease: Analysis from a Prospective Cohort Study. Journal of Clinical Medicine. 2023; 12(4):1676. https://doi.org/10.3390/jcm12041676

Chicago/Turabian Style

Li, Jiejie, Yuesong Pan, Mengxing Wang, Xia Meng, Jinxi Lin, Zixiao Li, Hao Li, Yilong Wang, Xingquan Zhao, Liping Liu, and et al. 2023. "Predictive Role of hsCRP in Recurrent Stroke Differed According to Severity of Cerebrovascular Disease: Analysis from a Prospective Cohort Study" Journal of Clinical Medicine 12, no. 4: 1676. https://doi.org/10.3390/jcm12041676

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop